ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC raised its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 41.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,780 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,187 shares during the period. Intech Investment Management LLC owned about 0.08% of ANI Pharmaceuticals worth $983,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in ANI Pharmaceuticals by 153.6% in the third quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company's stock valued at $771,000 after purchasing an additional 7,825 shares during the last quarter. Natixis Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 56.2% during the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company's stock valued at $1,085,000 after acquiring an additional 6,545 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after acquiring an additional 299 shares during the period. Quest Partners LLC boosted its position in shares of ANI Pharmaceuticals by 141.1% in the third quarter. Quest Partners LLC now owns 9,893 shares of the specialty pharmaceutical company's stock worth $590,000 after acquiring an additional 5,789 shares during the last quarter. Finally, Segall Bryant & Hamill LLC grew its holdings in ANI Pharmaceuticals by 1.7% in the third quarter. Segall Bryant & Hamill LLC now owns 44,872 shares of the specialty pharmaceutical company's stock valued at $2,677,000 after purchasing an additional 740 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. The trade was a 0.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the transaction, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,200 shares of company stock valued at $191,776. Insiders own 12.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ANIP shares. Leerink Partnrs raised ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. Guggenheim raised their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, March 14th. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded up $0.84 during trading hours on Wednesday, hitting $67.17. The company had a trading volume of 414,023 shares, compared to its average volume of 244,146. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.46 billion, a P/E ratio of -122.13 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $70.31. The business has a fifty day simple moving average of $59.88 and a 200-day simple moving average of $58.18.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.